StreetInsider.com News Articles

Celcuity Inc (CELC) PT Lowered to $147 at Leerink

Fri, 17 Jul 2026 08:36:14 -0400

Leerink analyst Andrew Berens lowered the price target on Celcuity Inc (NASDAQ: CELC) to $147.00 (from $157.00) while maintaining a Outperform rating.

Form SCHEDULE 13G Celcuity Inc. Filed by: BAKER BROS. ADVISORS LP

Thu, 16 Jul 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260716/26780770.html

Form SCHEDULE 13G Celcuity Inc. Filed by: BAKER BROS. ADVISORS LP

Thu, 16 Jul 2026 17:57:00 -0400

si-local-file:///var/storage/secattach/20260716/26780770.html

Form SCHEDULE 13D/A Celcuity Inc. Filed by: BAKER BROS. ADVISORS LP

Thu, 16 Jul 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260716/26780766.html

Form SCHEDULE 13D/A Celcuity Inc. Filed by: BAKER BROS. ADVISORS LP

Thu, 16 Jul 2026 17:51:00 -0400

si-local-file:///var/storage/secattach/20260716/26780766.html

Form 4 Celcuity Inc. For: Jul 14 Filed by: BAKER BROS. ADVISORS LP

Thu, 16 Jul 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260716/26780754.html

Form 4 Celcuity Inc. For: Jul 14 Filed by: BAKER BROS. ADVISORS LP

Thu, 16 Jul 2026 17:42:00 -0400

si-local-file:///var/storage/secattach/20260716/26780754.html

Increasing unusual put volume: ATAI MUU SPIR MAGS VLO KORU WEAT APPS PLAY DFTX ASTX EWS CELC BRUN

Thu, 16 Jul 2026 10:05:19 -0400

Increasing unusual put volume: ATAI MUU SPIR MAGS VLO KORU WEAT APPS PLAY DFTX ASTX EWS CELC BRUN

Increasing unusual call option volume: ANNX MUU FHN STT KORU PSIX ATAI FRO BHVN BN CXW SBAC SECZ CSX RRC

Thu, 16 Jul 2026 06:38:04 -0400

Increasing unusual call option volume: ANNX MUU FHN STT KORU PSIX ATAI FRO BHVN BN CXW SBAC SECZ CSX RRC

Form 8-K/A Celcuity Inc. For: Jul 14

Wed, 15 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26774155.html

Form 8-K/A Celcuity Inc. For: Jul 14

Wed, 15 Jul 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260715/26774155.html

Celcuity Inc (CELC) PT Raised to $155 at H.C. Wainwright

Wed, 15 Jul 2026 07:36:13 -0400

(Updated - July 15, 2026 7:36 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Celcuity Inc (NASDAQ: CELC) to $155.00 (from $145.00) while maintaining a Buy rating.

The analyst commented: "On July 14, 2026, three days ahead of the July 17 PDUFA date, the FDA approved REVTORPYK (gedatolisib) in combination with fulvestrant +/- palbociclib, for adults with HR+/HER2- PIK3CA wild-type (WT) locally advanced or metastatic breast cancer, following progression on or after at least one line of endocrine therapy. REVTORPYK received a label generally in-line with expectations, except for the requirement of a prophylactic steroid-based, alcohol-free mouth rinse

Celcuity Inc (CELC) PT Raised to $155 at H.C. Wainwright

Wed, 15 Jul 2026 07:36:13 -0400

(Updated - July 15, 2026 7:36 AM EDT)

H.C. Wainwright analyst Swayampakula Ramakanth raised the price target on Celcuity Inc (NASDAQ: CELC) to $155.00 (from $145.00) while maintaining a Buy rating.

Celcuity Inc (CELC) PT Raised to $177 at Citizens on Early Approval For Revtorpyk

Wed, 15 Jul 2026 07:23:11 -0400

Citizens analyst Silvan Turkcan raised the price target on Celcuity Inc (NASDAQ: CELC) to $177.00 (from $160.00) while maintaining a Market Outperform rating.

The analyst commented, "Celcuity's REVTORPYK (gedatolisib) in combination with fulvestrant, with or without palbociclib, won early approval and may be priced at a premium. The approval, which came several days ahead of schedule, currently applies to only ER+/HER2- BC patients without PIK3CA mutations, based on results from VIKTORIA-1 Study 1. The sNDA for the PIK3CA-mutant population is expected in 3Q26. The FDA approval sets the stage for Celcuity's transition to a commercial-stage company. We remain optimistic, and view

Celcuity Inc (CELC) PT Raised to $177 at Citizens on Early Approval For Revtorpyk

Wed, 15 Jul 2026 07:23:11 -0400

Citizens analyst Silvan Turkcan raised the price target on Celcuity Inc (NASDAQ: CELC) to $177.00 (from $160.00) while maintaining a Market Outperform rating.

Celcuity (CELC) Reiterated at Buy by Stifel on Revtorpyk Approval

Wed, 15 Jul 2026 07:22:34 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $175.00 price target on Celcuity Inc (NASDAQ: CELC).

The analyst commented, "FDA’s approval of Revtorpyk (gedatolisib) in 2L+ PIK3CAwt mBC patients – as part of both triplet (+fulvestrant/palbocilib) and doublet (+fulvestrant) regimens – is consistent with our/investor expectations and arrives a few days ahead of the July 17 PDUFA date. The product label similarly doesn’t appear to yield many surprises – although we note the incidence rate of TEAE-mediated discontinuations and dose modifications reported within the label appear meaningfully higher vs. what was implied by the 92%/100% relative dose intensities previously disclosed

Form 8-K Celcuity Inc. For: Jul 14

Wed, 15 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26770071.html

Form 8-K Celcuity Inc. For: Jul 14

Wed, 15 Jul 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20260715/26770071.html

Form 144 Celcuity Inc. Filed by: 667, L.P.

Tue, 14 Jul 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260714/26769490.html

Form 144 Celcuity Inc. Filed by: 667, L.P.

Tue, 14 Jul 2026 21:45:00 -0400

si-local-file:///var/storage/secattach/20260714/26769490.html

Form 144 Celcuity Inc. Filed by: Baker Brothers Life Sciences LP

Tue, 14 Jul 2026 21:43:00 -0400

si-local-file:///var/storage/secattach/20260714/26769487.html

Form 144 Celcuity Inc. Filed by: Baker Brothers Life Sciences LP

Tue, 14 Jul 2026 21:43:00 -0400

si-local-file:///var/storage/secattach/20260714/26769487.html

FDA approves Celcuity's gedatolisib for a breast cancer subtype

Tue, 14 Jul 2026 16:53:49 -0400

The U.S. Food and Drug Administration has approved Celcuity Inc.'s (Nasdaq: CELC) REVTORPYK (gedatolisib) for the treatment of adult patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation, following progression on at least one line of endocrine therapy in the metastatic setting.

The approval is based on results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial. In that trial, the REVTORPYK triplet — gedatolisib combined with palbociclib and fulvestrant — produced a median progression-free survival of 9.3 months, compared with 2.0 months for fulvestrant alone, a difference of 7.3 months (HR=0.24; p<0.0001).

FDA approves Celcuity's gedatolisib for a breast cancer subtype

Tue, 14 Jul 2026 16:53:49 -0400

FDA approves Celcuity's gedatolisib for a breast cancer subtype

Tue, 14 Jul 2026 16:53:49 -0400